Loss of CD20 expression following treatment with rituximab (chimaeric monoclonal anti-CD20): A retrospective cohort analysis

British Journal of Haematology

Volumn 114, Issue 4, 2001, Pages 881-883

  Foran, J M ^a   Norton, A J ^a   Micallef, I N M ^a   Taussig, D C ^a   Amess, J A L ^a   Rohatiner, A Z S ^a   Lister, T A ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

B cell; CD20; Immunohistochemistry; Non Hodgkin's lymphoma; Rituximab

Indexed keywords

CD20 ANTIGEN; CD3 ANTIGEN; CD79A ANTIGEN; CHIMERIC ANTIBODY; MONOCLONAL ANTIBODY; RITUXIMAB;

ANTIGEN EXPRESSION; ARTICLE; B LYMPHOCYTE; BONE MARROW; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC PROCEDURE; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; LYMPH NODE BIOPSY; LYMPHOCYTIC INFILTRATION; MAJOR CLINICAL STUDY; MALE; NONHODGKIN LYMPHOMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; T LYMPHOCYTE;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD; ANTIGENS, CD20; ANTIGENS, CD3; ANTIGENS, CD79; ANTINEOPLASTIC AGENTS; B-LYMPHOCYTES; BONE MARROW CELLS; HUMANS; IMMUNOPHENOTYPING; IMMUNOTHERAPY; LEUKEMIC INFILTRATION; LYMPHOMA, B-CELL; RECEPTORS, ANTIGEN, B-CELL; RETROSPECTIVE STUDIES; T-LYMPHOCYTES, CYTOTOXIC;

EID: 0034786134     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.2001.03019.x     Document Type: Article

References (12)

1. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: A multicenter phase II study
2. Therapy of B-cell lymphoma with anti-CD20 antibodies can result in the loss of CD20 antigen expression
3. Lymphoid aggregates in bone marrow mimic residual lymphoma after rituximab therapy for non-Hodgkin lymphoma
4. European phase II study of rituximab (chimaeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma, and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma
5. A UK multicentre phase II study of rituximab (chimaeric anti-CD20 monoclonal antibody) in patients with follicular lymphoma, with PCR monitoring of molecular response
6. CD20-negative relapse in B-cell lymphoma after treatment with rituximab
7. Emergence of idiotype variants during treatment of B-cell lymphoma with anti-idiotype antibodies
8. Brief, high-temperature heat denaturation (pressure cooking). A simple and effective method of antigen retrieval for routinely processed tissues
9. The diagnosis of low-grade peripheral B-cell neoplasms in bone marrow trephines
10. Endocytosis and degradation of monoclonal antibodies targeting human B-cell malignancies
11. Clonal selection of CD20-negative non-Hodgkin's lymphoma cells after treatment with anti-CD20 antibody rituximab
12. CD20-negative relapse after 1311-anti-CD20 therapy